GlassScriptPhysician profile
Virginia Moye
NPI 1871908228
$4,632.70
in general payments reported to CMS, 2019-2025
27 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $119 · 2021: $129 · 2022: $824 · 2023: $1,426 · 2024: $1,368 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,959.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $947.25 | 2019-2025 | |
| Genzyme Corporation | $475.86 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $367.01 | 2019-2024 | Ilumya, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $333.50 | 2022-2024 | Sotyktu |
| Pfizer INC. | $287.49 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $283.52 | 2019-2025 | Dupixent |
| Janssen Biotech, INC. | $223.33 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $211.66 | 2019-2024 | |
| Amgen INC. | $202.11 | 2022-2024 | Otezla |
| Lilly USA, LLC | $162.65 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $161.11 | 2022-2024 | Adbry |
| Ucb, INC. | $157.84 | 2019-2024 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $142.82 | 2023 | |
| Galderma Laboratories, L.P. | $103.38 | 2019-2025 | Aklief |
| Incyte Corporation | $95.74 | 2022-2024 | Opzelura |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $95.38 | 2022-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.80 | 2023-2024 | Spevigo |
| Jazz Pharmaceuticals INC. | $75.39 | 2024 | |
| Celgene Corporation | $48.61 | 2019 | |
| Almirall LLC | $38.48 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.20 | 2019 | |
| Epi Health, LLC | $25.43 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $21.31 | 2021 | |
| Organogenesis INC. | $17.55 | 2023 | Puraply |
| Dusa Pharmaceuticals, INC. | $17.02 | 2019 | |
| Dermira, INC. | $15.95 | 2019 | |
| Biofrontera INC. | $7.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Moye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.